The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, exosome-loaded paclitaxel (ExoPAC), delivered through either oral or intravenous routes, has been shown to increase bioavailability and tumor specificity [73].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [73]
In the citing paper
“Research has shown that loading paclitaxel into exosomes not only significantly reduces off-target toxicity but also enhances the drug concentration in cancer cells, thereby improving therapeutic efficacy.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [73]
In the citing paper
“This advantage is associated with the distinctive uptake mechanisms of exosomes [118].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [118]
In the citing paper
“In vitro and in vivo studies have indicated that exosomes, functioning as drug carriers, are capable of bypassing the Pgp-1-mediated efflux system and effectively delivering drugs to tumor cells.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Wiklander, O. P. B., Nordin, J. Z., O'Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I., Vader, P., Lee, Y., Sork, H., Seow, Y., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.26316 · Cited by 1,730
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006) · Leukemia · doi:10.1038/sj.leu.2404296 · Cited by 1,340
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733 · cited 1×
“To date, there has been limited success in overcoming drug resistance in cancers through the use of novel small molecule chemotherapeutics (5, 6), or nanoformulations of existing chemotherapeutics (7-9).”
Johnsen, K. B., Gudbergsson, J. M., Skov, M. N., Pilgaard, L., Moos, T., & Duroux, M. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.005 · Cited by 704
Microvesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Flagged first, then by citations
Research works printed but not linked: 41
- Gharpure, 2015, Nanotechnology: future of oncotherapy, Clin Cancer Res, 21, 3121, 10.1158/1078-0432.CCR-14-1189 · DOI
- Abu Lila, 2013, The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage, J Control Release, 172, 38, 10.1016/j.jconrel.2013.07.026 · DOI · Paper page
- Hayeshi, 2006, The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux, Eur J Pharm Sci, 29, 70, 10.1016/j.ejps.2006.05.009 · DOI
- Bauer, 2005, A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia, Leuk Res, 29, 263, 10.1016/j.leukres.2004.07.002 · DOI
- Simpson, 2008, Proteomic profiling of exosomes: current perspectives, Proteomics, 8, 4083, 10.1002/pmic.200800109 · DOI
- Kalani, 2014, Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics, Mol Neurobiol, 49, 590, 10.1007/s12035-013-8544-1 · DOI
- Dong, 2010, Nanomedicinal strategies to treat multidrug-resistant tumors: current progress, Nanomedicine (Lond), 5, 597, 10.2217/nnm.10.35 · DOI
- Yang, 2014, Nanomedicine to overcome cancer multidrug resistance, Curr Drug Metab, 15, 632, 10.2174/1389200215666140926154443 · DOI
- Koziara, 2006, In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors, J Control Release, 112, 312, 10.1016/j.jconrel.2006.03.001 · DOI
- Kalani, 2014, Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia, Life Sci, 107, 1, 10.1016/j.lfs.2014.04.018 · DOI
- Mathivanan, 2010, Exosomes: extracellular organelles important in intercellular communication, J Proteome, 73, 1907, 10.1016/j.jprot.2010.06.006 · DOI
- Alvarez-Erviti, 2011, Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes, Nat Biotechnol, 29, 341, 10.1038/nbt.1807 · DOI · Paper page
- Wahlgren, 2012, Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes, Nucleic Acids Res, 40, e130, 10.1093/nar/gks463 · DOI
- Shtam, 2013, Exosomes are natural carriers of exogenous siRNA to human cells in vitro, Cell Commun Signal, 11, 88, 10.1186/1478-811X-11-88 · DOI · Paper page
- Pan, 2012, Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi), Gut, 61, 1330, 10.1136/gutjnl-2011-300449 · DOI
- Chen, 2014, Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells, Hepatology, 59, 1118, 10.1002/hep.26768 · DOI
- Sun, 2010, A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes, Mol Ther, 18, 1606, 10.1038/mt.2010.105 · DOI
- Zhuang, 2011, Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain, Mol Ther, 19, 1769, 10.1038/mt.2011.164 · DOI · Paper page
- Tian, 2014, A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy, Biomaterials, 35, 2383, 10.1016/j.biomaterials.2013.11.083 · DOI
- Thery, 2009, Membrane vesicles as conveyors of immune responses, Nat Rev Immunol, 9, 581, 10.1038/nri2567 · DOI
- Pidaparti, 2012, Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly, Pediatr Blood Cancer, 59, 436, 10.1002/pbc.23380 · DOI
- Batrakova, 2001, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion, Br J Cancer, 85, 1987, 10.1054/bjoc.2001.2165 · DOI
- Haney, 2015, Exosomes as drug delivery vehicles for Parkinson's disease therapy, J Control Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
- Laulagnier, 2005, Characterization of exosome subpopulations from RBL-2H3 cells using fluorescent lipids, Blood Cells Mol Dis, 35, 116, 10.1016/j.bcmd.2005.05.010 · DOI
- Boldytev, 2006, A synthesis and properties of new 4,4-difluoro-3a,4a-diaza-s-indacene (BODIPY)-labeled lipids, Bioorg Khim, 32, 87
- Batrakova, 2010, Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers, J Control Release, 143, 290, 10.1016/j.jconrel.2010.01.004 · DOI
- Batrakova, 2006, Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85, Mol Pharm, 3, 113, 10.1021/mp050050g · DOI
- Ferrari, 1990, MTT colorimetric assay for testing macrophage cytotoxic activity in vitro, J Immunol Methods, 131, 165, 10.1016/0022-1759(90)90187-Z · DOI
- Sena-Esteves, 2004, Optimized large-scale production of high titer lentivirus vector pseudotypes, J Virol Methods, 122, 131, 10.1016/j.jviromet.2004.08.017 · DOI
- Brynskikh, 2010, Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease, Nanomedicine (Lond), 5, 379, 10.2217/nnm.10.7 · DOI
- De Jong, 2008, Drug delivery and nanoparticles: applications and hazards, Int J Nanomedicine, 3, 133, 10.2147/IJN.S596 · DOI
- Batrakova, 1999, Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells, Pharm Res, 16, 1373, 10.1023/A:1018942823676 · DOI
- Batrakova, 2003, Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells, J Pharmacol Exp Ther, 304, 845, 10.1124/jpet.102.043307 · DOI
- Batrakova, 2003, Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85, Pharm Res, 20, 1581, 10.1023/A:1026179132599 · DOI
- Kalra, 2013, Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma, Proteomics, 13, 3354, 10.1002/pmic.201300282 · DOI
- Mulcahy, 2014, Routes and mechanisms of extracellular vesicle uptake, J Extracell Vesicles, 3, 10.3402/jev.v3.24641 · DOI · Paper page
- Safaei, 2005, Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells, Mol Cancer Ther, 4, 1595, 10.1158/1535-7163.MCT-05-0102 · DOI
- Yamagishi, 2013, P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration, J Biol Chem, 288, 31761, 10.1074/jbc.M113.514091 · DOI
- Pascucci, 2014, Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery, J Control Release, 192, 262, 10.1016/j.jconrel.2014.07.042 · DOI · Paper page
- Finn, 2012, Immuno-oncology: understanding the function and dysfunction of the immune system in cancer, Ann Oncol, 23, viii6, 10.1093/annonc/mds256 · DOI
- Parolini, 2009, Microenvironmental pH is a key factor for exosome traffic in tumor cells, J Biol Chem, 284, 34211, 10.1074/jbc.M109.041152 · DOI
Cited by
Sorted by citations
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Engineering exosomes for targeted drug delivery
Liang, Y., Duan, L., Lu, J., & Xia, J. (2021) · Theranostics · doi:10.7150/thno.52570 · Cited by 1,547
Zhang, Y., Bi, J., Huang, J., Tang, Y., Du, S., & Li, P. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s264498 · Cited by 1,323
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Jia, G., Han, Y., An, Y., Ding, Y., He, C., Wang, X., & Tang, Q. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.029 · Cited by 753
Metadata
- Authors
- Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., Hingtgen, S. D., Kabanov, A. V., & Batrakova, E. V.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 12
- Issue
- 3
- Pages
- 655-664
- ISSN
- 1549-9634
- PMC
- PMC4809755
- Cited by
- 1,410
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
